4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)-
- CAS No.
- 2044686-42-0
- Chemical Name:
- 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)-
- Synonyms
- TP1287;TP-1287;TP 1287;4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)-
- CBNumber:
- CB39764737
- Molecular Formula:
- C21H21ClNO8P
- Molecular Weight:
- 481.82
- MDL Number:
- MOL File:
- 2044686-42-0.mol
- MSDS File:
- SDS
- TDS File:
- TDS
4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)- Properties
| Boiling point | 717.1±70.0 °C(Predicted) |
|---|---|
| Density | 1.576±0.06 g/cm3(Predicted) |
| pka | 1.58±0.10(Predicted) |
| form | Solid |
| color | Light yellow to yellow |
| FDA UNII | 7MPP85IIJ3 |
4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)- price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0675229 | TP-1287 95.93% | 2044686-42-0 | 5mg | $596 | 2026-06-04 | Buy |
| ChemScene | CS-0675229 | TP-1287 95.93% | 2044686-42-0 | 10mg | $953 | 2026-06-04 | Buy |
| ChemScene | CS-0675229 | TP-1287 95.93% | 2044686-42-0 | 25mg | $1733 | 2026-06-04 | Buy |
| ChemScene | CS-0675229 | TP-1287 95.93% | 2044686-42-0 | 50mg | $2773 | 2026-06-04 | Buy |
| ChemScene | CS-0675229 | TP-1287 95.93% | 2044686-42-0 | 100mg | $4442 | 2026-06-04 | Buy |
4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)- Chemical Properties, Uses, Production
Uses
TP-1287, a prodrug of Alvocidib (HY-10005), is an orally active CDK9 inhibitor[1].
in vivo
TP-1287 (2.5-15 mg/kg; oral) suppresses tumor growth in models of multiple myeloma[1].
TP-1287 is highly soluble over a broader pH range than Alvocidib (HY-10005) and is efficiently metabolized to the parent compound in vivo, following oral administration[2].
| Animal Model: | RPMI-8226 xenograft model for multiple myeloma[1] |
| Dosage: | 2.5, 7.5, and 15 mg/kg |
| Administration: | Oral |
| Result: | Achieved tumor growth inhibition (%TGI) of 56.0, 76.6, and 93.9% at doses of 2.5, 7.5, and 15 mg/kg, respectively. |
IC 50
CDK9
References
[1] Tyagi E, et al. The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma. Blood, 2018, 132: 3269.
[2] Kim W, et al. TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib. Cancer Research, 2017, 77(13_Supplement): 5133-5133.
4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)- Preparation Products And Raw materials
Raw materials
Preparation Products
4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)- Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd. | 17702719238 | sales@sun-shinechem.com | China | 1197 | 64 |
| Wuhan Sun-shine Bio-technology Corporation Limited | +86-027-6552-2453 | sales@sun-shinechem.com | China | 725 | 58 |
| Chunchuang (Wuhan) Technology Co., Ltd | 15727060112 | yutianchun2007@126.com | China | 9869 | 58 |
| Shanghai Dexuan Pharmaceutical Technology Co., Ltd | dexuanyiyao@126.com | dexuanyiyao@126.com | China | 9470 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Shandong Dayou Pharmaceutical Research and Development Co., Ltd. | hanfangpharma@126.com 15165037910 | hanfangpharma@126.com | China | 25800 | 58 |
| ChemOrigin Pharm | 15026428026 19002516454 | ChemOrigin@126.com | China | 1589 | 58 |
| TargetMol Chemicals Inc. | 13564774135 | marketing@targetmol.com | United States | 19950 | 58 |





